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Objective: After exhaustion of all conventional arteriovenous (AV) access options, an alternative approach is an
arterioarterial conduit. The purpose of this study was to examine the utility of an axillary-axillary (AA) interarterial (IA)
access in this subset of patients.
Methods: A retrospective review was performed of all patients who underwent placement of an AA IA access. Patients were
observed for functional aspects and complications. Outcomes were determined according to the Society for Vascular
Surgery/American Association for Vascular Surgery standards for reports for dealing with AV accesses.
Results: Twenty patients (median age, 59 years; range, 41-82 years) underwent AA IA access placement under general
anesthesia between May 2001 and December 2004. Exhausted upper extremity AV access options were found in 14
patients (70%), with central vein occlusion in 5 patients (25%), and 12 patients (60%) had ischemia from steal syndrome.
High-output cardiac failure was present in one patient. Median follow-up was 7.4 months (range, 0.5-45.3 months). The
30-day perioperative mortality rate was 5%. There was one (5%) early access thrombosis that resulted in moderate
ischemia. Late access thrombosis occurred in three patients (15%), and all cases were asymptomatic. Early postoperative
bleeding necessitated surgical intervention in four patients (20%). Late graft infection (n 1; 5%) occurred after repeated
thrombectomy. The primary and secondary patency rate was 90% and 93%, respectively, at 6 months.
Conclusions: This short-term initial study showed that the AA IA loop access could be implanted with acceptable
perioperative morbidity and with an excellent secondary patency rate. Further follow-up is necessary to determine the
long-term complication rate and to allow more reasonable comparison with other methods of access. ( J Vasc Surg 2005;
42:290-5.)Native arteriovenous fistulas (NAVFs) and arterio-
venous grafts (AVGs) in the upper extremity are the first
and second choice for chronic hemodialysis access, respec-
tively, in terms of long-term patency.1 After exhaustion of
all conventional arteriovenous (AV) access options, perma-
nent dialysis catheters are unavoidable in some patients.
This is, however, associated with increased patient discom-
fort and higher morbidity, mainly because of thrombosis
and infection with a shorter expected durability.2,3 More-
over, the lower blood flow rates compared with AV access
can lead to compromised dialysis adequacy.4 An alternative
procedure for permanent dialysis access is an arterioarterial
loop access positioned on the chest. Experiences with in-
terarterial (IA) approaches for dialysis are limited,5-7 and,
to our knowledge, none has been published about the
axillary location. We report the short-term results after
insertion of 20 axillary-axillary (AA) IA conduits regarding
patency and complications.
PATIENTS AND METHODS
All patients included in the study agreed to the condi-
tions of the procedure by signing a consent form. All
patients who underwent placement of an AA IA chest loop
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290conduit at our hospital were reviewed. Patients have been
monitored for a median of 7.4 months (range, 0.5-45.3
months). Nine patients have completed at least 12 months
of follow-up. Information regarding patient demographic
data, preoperative diagnostic workups, procedures, and
outcomes was collected through chart review and fol-
low-up visits, including duplex ultrasound examination.
Since October 2003, all patients have been enrolled in a
prospective manner with follow-up every 3 months. Preop-
erative evaluation included careful assessment of the vascu-
lar anatomy. Arterial examination included pulse assess-
ment and bilateral upper extremity blood pressure (BP)
measurement. All patients underwent duplex ultrasound
scanning mapping (Sonoline Sienna; Siemens, München,
Germany). The velocity of blood flow was measured in the
axillary artery before and after access placement by using a
5-MHz scanning probe. Furthermore, the flow rate was
calculated bymeasuring at three different points of the loop
conduit. The choice of access site was made on the basis of
the results of clinical examination and imaging. The dialysis
department was asked for the duration of dialysis (hours per
week) on a functional NAVF or AVG in the past and after
implantation of AA IA access.
Technique for creation of an AA IA chest loop
conduit. Primary access procedures were performed with
the patient under general anesthesia (GA). Revision for
hematoma or occlusion was performed under GA or local
anesthesia (LA), as considered appropriate by the operating
team. Two grams of cephazolin was administered 30 min-
utes before the start of the operation. A diagram of the
operative technique for creation of an AA IA access is
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made, and the axillary artery was identified after separation
of fibers of the pectoralis major muscle and transsectioning
of the pectoralis minor muscle just below the coracoid
process. The brachial nerve plexus was carefully spared.
After division of the axillary artery, a polytetrafluoroethyl-
ene (PTFE) graft (Gore-Tex; W. L. Gore and Associates,
Inc, Flagstaff, Ariz) or the greater saphenous vein (in case of
recurrent infections of prosthetic grafts, dialysis catheters,
or both) was interpositioned after configuration of a sub-
cutaneously tunneled loop on the chest. The size of the
PTFE graft was chosen according to the diameter of the
axillary artery during operation. Unfractionated heparin
3000 IU was given intravenously before clamping of the
axillary artery. A drain was left in the infraclavicular wound,
as considered appropriate by the surgeon. Three to five days
after operation, patients received acetylsalicylic acid (ASA),
clopidogrel, or phenprocoumon, according to their preop-
erative treatment. After March 2004, each patient without
previous antiplatelet treatment or anticoagulation received
clopidogrel. The loop conduit was allowed to mature for at
least 2 weeks before puncture.
Statistical analysis. Data were entered into a Mi-
crosoft Excel 2000 (Microsoft Corp, Redmond, Wash)
Fig 1. Drawing of the axillary-axillary interarterial access with
illustration of the cannulation; the right axillary artery has been
divided, followed by interposition of a subcutaneous tunneled
prosthetic or autogenous chest access.spreadsheet for analysis. Statistical analysis was performedwith SigmaStat forWindows, version 3.00 (Systat Software,
Point Richmond, Calif). Survival of the patients and pri-
mary and secondary patency rates of dialysis accesses were
calculated with Kaplan-Meier survival estimates8 in accor-
dance with the Society for Vascular Surgery/American
Association for Vascular Surgery reporting standards for
the lower extremity9 and AV access.10 Censored end points
were death, transfer of care to another institution, trans-
plantation, loss to follow-up, and access survival at the last
examination.
RESULTS
From May 2001 to October 2004, 20 patients under-
went AA IA access (PTFE: n 19, 90%; greater saphenous
vein: n  2, 10%) under GA. The preoperative patient
characteristics are described in Table I. The median fol-
low-up was 7.4 months (range, 0.5-45.3 months). The
patients had received dialysis for an average of 60 months
(range, 1-226months). A total of 85% of patients hadmore
than 1 NAVF and 55% had more than 1 AVG as prior
permanent accesses, whereas 85% actively underwent dial-
ysis through catheters. The indications for AA IA access
placement are listed in Table II. Exhausted access options,
ie, no possibility to establish a wrist or an elbow AV fistula
or an upper extremity AVG, were found in 14 patients
(70%), with central vein occlusion in 5 patients (25%),
documented by phlebography. Twelve patients (60%) ex-
perienced ischemia from steal syndrome, which was diag-
nosed in our department by angiography (four patients) or
duplex ultrasound examination (six patients). Two patients
were determined through chart review to have ischemic
steal. High-output cardiac failure was present in one pa-
tient. The procedural characteristics are listed in Table III.
The mean operation time was 100 minutes (range, 65-125
minutes).
The median hospital length of stay after AA IA access
placement was 5.5 days (range, 2-14 days). The first can-
nulation of AA IA access was performed after a median of
3.8 weeks (range, 2.1-10.4 weeks). Of note, the physio-
Table I. Preoperative patient characteristics
Variable Data
Sex, n (%)
Male 5 (25%)
Female 15 (75%)
Age (y)
Median 59
Range 41-82
Associated medical condition, n (%)
Diabetes mellitus 6 (30%)
Hypertension 9 (45%)
Coronary artery disease 14 (70%)
Cerebrovascular disease 3 (15%)
Body mass index (kg/m2)
Median 28
Range 25-34logic thrill used to confirm the adequacy of the access was
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Instead, a pulse could be easily palpated on the chest. The
30-day perioperative mortality rate was 5%. The death
occurred 15 days after placement of AA IA access and was
unrelated to the operation. No autopsy was performed.
Fifteen revisional operations, which were undertaken with
patients under GA (71%) or LA (29%), were necessary in six
patients (30%). Revisional procedures were followed by
interventional therapy in 10% (percutaneous transluminal
angioplasty alone, n 1; percutaneous transluminal angio-
plasty and stent, n  1). Early postoperative bleeding
required surgical intervention in four patients (20%).
Bleeding was derived from injury to the minor pectoralis
muscle in all cases. No blood transfusion was required.
There was one (5%) early (30 days) access thrombosis
related to postoperative hematoma. It resulted in symp-
tomatic hand ischemia, with complete recovery after
thrombectomy. Late (30 days) access thrombosis oc-
curred in three patients (15%) without development of
peripheral ischemia. In this subset of patients, a resistance
to activated protein C due to homozygous mutation of
factor V (n  2) or hypotension (n  2) was found. One
graft infection developed after the third thrombectomy for
recurrent thrombotic occlusion despite anticoagulation.
The access was removed, and the axillary artery was recon-
structed by an autogenous greater saphenous vein. The
following dialysis was performed through a tunneled cath-
TABLE II. Indications for AA IA access placement
Exhausted
access Steal symdrome Cardi
n CVO n Intervention n
1 1 N
1 NAVF CL, LIG
1 NAVF IL, LIG
1 c
1 1 *
1 1 *
1 NAVF CL, LIG
1 NAVF CL, LIG
1 1 AVG CL, LIG
1 c
1 1 *
1 a, BI
1 1 *
1 c
1
1 NAVF CL, B, LIG
1 1 *
1
1
1 s, CL
14 5 12 1
70 25 60 5
Abbreviations: a  axillary; b-c  brachio-cephalic; B  Banding; c  supe
IL  ipsilateral; j  jugular; LIG  ligation; s  subclavian.
*Steal-syndrome disappeared after thrombotic occlusion of AV-access.eter until a fatal cardiac arrest occurred 20 days later with-out symptoms or signs of a continuing wound infection.
Before operation, 25% of the patients received antiplatelet
treatment (ASA, n  4; clopidogrel, n  1), 10% in
combination with phenprocoumon, and 5% received anti-
coagulation alone. After placement of AA IA access, 65%
received antiplatelets (ASA, n  6; clopidogrel, n  7). In
one patient taking clopidogrel, we noted a prolonged
puncture site that bled up to 30 minutes. No other local
complications (pseudoaneurysm, seroma, or lymphocele)
or remote complications (venous hypertension, neuropa-
thy, and congestive heart failure) were detected. The pri-
mary (Fig 2) and secondary (Fig 3) patency rate was 90%
and 93%, respectively, at 6 months. All nonoccluded con-
duits had been functioning well up to the time of the
censored end point, without differences between PTFE
and autogenous vein. During follow-up, two patients un-
derwent successful kidney transplantations.
No significant difference of BP measurements and peak
systolic velocity values at duplex scan existed between the
corresponding and the contralateral arm before operation
and at follow-up. We attempted to measure BP in all
patients with graft occlusion, but it was not detectable.
Because this was a retrospective analysis, a systematic du-
plex ultrasound measurement of the peripheral circulation
was not performed distal to an occluded access. Regarding
our documented measurements, graft occlusion induced a
monophasic flow and a lower Vmax compared with preop-
suffiency Hemodialysis
rvention
Present Previous
NAVF Catheter NAVF AVG
CL, B, LIG b-c, CL 3 1
j, IL 2 1
b-c, IL 3 2
f 2 2
s, CL 2 2
f 3 1
f 3 1
f 2 1
j, IL 1 1
f 2 2
s, CL 2 2
j, IL 1 1
f 2 3
f 2 2
J, IL 2 2
j, CL 2 2
s, CL 1 1
f 2 2
s, CL 2 2
b-c, CL 2 3
3 17 2, 1 1, 7
15 85 (per patient)
ena cava; CL  contralateral; CVO  central vein occlusion; f  femoral;ac in
Inte
AVF
rior verative measurements, but these data are incomplete.
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(range, 55-250 mL/min) on the day of discharge, without
significant differences in measurements at 3 and 6 months.
The withdrawal of blood was successfully adjusted to 250
to 300 mL/min by the nephrologist. The duration of
dialysis was comparable, with a median of 13.5 h/wk
Fig 3. Kaplan-Meier curve for secondary patency, including stan-
dard error bars.
Fig 2. Kaplan-Meier curve for primary patency, including stan-
dard error bars (*standard error exceeds 10% at 6.3 months).(range, 12-16 h/wk) before and 12 h/wk (range, 9-18h/wk) after AA IA access placement (P  .35). No diffi-
culties with cannulation were reported by the nephrologist.
DISCUSSION
National Kidney Foundation-Dialysis Outcomes Qual-
ity Initiative guidelines recommend the use of NAVFs as
the vascular access of first choice11,12 before implantation
of AVGs. As the population requiring hemodialysis
grows,13 however, it is increasingly common to encounter
patients with exhausted options for vascular access, because
each access has a limited lifetime. This is mainly attributable
to intimal hyperplasia at the venous anastomosis and the
venous outflow tract and, as a result of indwelling catheters,
to central venous stenosis.14,15 Cuffed tunneled central
venous catheters are, therefore, by no means an ideal alter-
native method for dialysis access. Their use as a permanent
vascular access should be discouraged because of infection,
thrombosis, and displacement,12 which are associated with
high morbidity and mortality. A new approach for dialysis
access is an AA conduit, for which problems of venous
outflow obstruction do not exist. Few data have been
published about this treatment option,5-7 mainly as a sub-
cutaneous loop positioned on the thigh. To our knowl-
edge, the chest position for inserting an IA loop has not yet
been described.
We defined three main indications for AA IA access
insertion: exhausted upper extremity access options, in-
cluding central venous occlusion; ischemic steal syndrome;
and cardiac failure. For the first group, AA or axillary-
jugular AV chest access has been well described in the
absence of central vein occlusion. The incidence of throm-
bosis and infection was presented to be comparable with
conventional arm bridge fistulas.16 With these procedures
in the past, however, we experienced disappointing results
regarding patency despite unhindered central venous flow.
In patients with occlusion of central veins, the thigh AV
access might be a suitable alternative, but a high associated
Table III. Procedural characteristics
Variable Data
Site of procedure, n (%)
Right 12 (60%)
Left 8 (40%)
Conduit material, n (%)
PTFE 6 mm standard wall 10 (50%)
PTFE 7 mm 4 (20%)
PTFE 8 mm 4 (20%)
Autologous vein 2 (10%)
Operation time (min)
Median 100
Range 65-125
Postoperative coagulation management, n (%)
ASA 6 (30%)
Clopidogrel 7 (35%)
Phenprocoumon 1 (5%)
Phenprocoumon/ASA 2 (10%)
PTFE, Polytetrafluoroethylene; ASA, acetylsalicylic acid.infection rate of 11% to 41%17,18 and more common arte-
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rationale for us to develop the arterioarterial chest access
option. Other approaches, such as anastomosis to the right
atrial appendage20 through a median sternotomy or to the
renal vein,21 were excluded, because we considered these to
be more heroic and complex access configurations.
The second group consisted of patients with sustained
ischemic steal syndrome until spontaneous AV access oc-
clusion occurred. In other patients, the indication for AA
IA access placement was poor peripheral arteries of the
forearms diagnosed by angiography or duplex ultrasound
examination. The technique of distal artery ligation and
revascularisation22 was interpreted by us not to be suitable
in these patients.
In a third group suitable for the arterioarterial access
placement, we treated a patient with high-output cardiac
failure, in whom the ligation of elbowNAVFwas ultimately
necessary. We demonstrated an excellent short-term pa-
tency rate for the AA IA conduit.
The 30-day mortality rate was 5% and was interpreted
to be unrelated to the access procedure, because the death
occurred 15 days after operation and because there was no
clinical deterioration in the immediate postoperative pe-
riod. The ultimate cause of death remains, however, unde-
tected, because no autopsy was performed.
We concede that the role of AA IA access in a popula-
tion of patients with end-stage renal disease and complex
access problems is debatable in light of the risk of using GA.
It is therefore mandatory that each patient who is a candi-
date for this approach be thoroughly examined by the
anesthesiologist. If the anesthesiologist is in doubt, the
patient should excluded from this treatment. Although the
procedure could be performed with the patient under LA,
we would not recommend it, because unexpected move-
ments of the patient could induce tears of the soft axillary
artery while the end-to-end anastomosis is performed. Re-
visional procedures such as thrombectomy, however, can
easily be performed with LA.
Admittedly, the revisional rate was high, with 15 pro-
cedures on 6 patients (30%). The bleeding complications (n
 4) were observed in the beginning of the study and
originated mainly from the pectoralis muscles. Because we
paid special attention to meticulous preparation for expos-
ing the axillary artery, no more bleeding complications
were seen with the last 13 patients.
Most revisions were undertaken for thrombotic occlu-
sion (n  10). Early (30 days) thrombotic occlusion of
the conduit was due to compression of hematoma in one
patient, whereas the other three patients with late (30
days) occlusion of the loop showed activated protein C
resistance, hypotension, or both, and this may have con-
tributed to thrombosis. According to the established anti-
thrombotic therapy for maintaining the patency of vascular
grafts after lower extremity bypass operations,23 we pro-
ceeded to treat every patient without previous antiplatelet
therapy with clopidogrel, but not in combination with
ASA. There are no data supporting this practice, but we are
confident because no further primary occlusion has beendetected and because no major bleeding has occurred in
this (admittedly short-term) follow-up. ASA was not cho-
sen because it is known to increase the risk of gastrointes-
tinal bleeding in the uremic population,24 and among
nonuremic patients, ASA is more likely than clopidogrel to
cause gastrointestinal bleeding.25 Because no studies exist
of the effects of monotherapy with clopidogrel on bleeding
in the uremic population, however, the potential bleeding
risk among these patients has to be recognized. Further-
more, the concurrent administration of ASA and clopi-
dogrel should be avoided, because a significantly increased
risk of bleeding in uremic patients has been shown.26
Of note, acute occlusion of the AA IA conduit will be
compensated sufficiently through the arterial collateral sup-
ply of the shoulder.27 Only one patient developed symp-
tomatic hand ischemia, but at that time, a hyperflow AV
fistula was present on the corresponding limb. After liga-
tion, hand ischemia never occurred again despite two other
thrombotic occlusions of the loop graft.
Contrary to reported upper extremity thromboembo-
lism after AA28 grafts for arterial occlusive diseases, throm-
boembolism or thrombus propagation has not been ob-
served clinically with patent or occluded AA IA access
grafts, although subclinical episodes could not be ruled
out. Because thrombectomy of an occluded AA IA access
theoretically entails a higher risk of embolic complication,
this might be avoidable by choosing the brachial artery for
revisional operation. Until now, however, we have per-
formed this procedure by opening the graft near the anas-
tomoses to preserve the option of local extraction of the
neointimal hyperplasia, which we detected in two patients.
In one case, we supplemented this procedure by percuta-
neous transluminal angioplasty and stent implantation.
This loop graft still functions well after a follow-up of 40
months, but it is only a single case. We believe, however,
that endovascular revision of an arterioarterial access, in
contrast to an AV access, leads to a more durable ef-
fect.29,30 This has to be proven in longer follow-up studies.
We have no experience with occluded AA IA access left
in place between the proximal and distal arterial circulation
regarding late thromboembolism or thrombus propaga-
tion. We would therefore recommend axillary reconstruc-
tion either by end-to-end suturing of the divided and
sparingly shortened axillary artery or by an interpositional
vein graft.28
One loop graft infection developed that was localized at
the anastomosis after three thrombectomies for thrombotic
occlusion despite anticoagulation with therapeutic Interna-
tional normalized ratio. We interpreted this as a fateful
event, which could occur naturally when dealing with pros-
thetic material, especially after repeated operation. A disad-
vantage of interposing the access between the proximal and
distal arterial circulation might be that the arm could be at
risk for progressive infection if the graft or a puncture site
were to become infected. This was not observed in our
patient, even after conservative treatment of the infected
access with antibiotics for 7 days. A longer follow-up,
however, is mandatory for determining whether progres-
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more, the renal unit staff has to bear in mind that drug
administration through the arterioarterial loop graft is pro-
hibited. Therefore, an additional intravenous line is neces-
sary in some patients, and this may be a relevant consider-
ation in light of the paucity of residual superficial veins.
According to the treating nephrologists, however, this issue
has not been significant.
With a median access flow of 150 to 160 mL/min at
rest and an adjusted blood withdrawal of 200 to 250
mL/min in our patients, we could demonstrate the effec-
tiveness of dialysis with the IA approach. Furthermore,
dialysis hours per week were comparable before and after
surgery.
One drawback regarding the study and the procedure is
the limited number of patients with long-term follow-up.
However, the patency for all prosthetic and autogenous
access procedures is limited and is usually quoted in the 6-
to 18-month range. Because the analysis was performed in
a retrospective manner, no reliable ultrasound data have
been collected distal to occluded loop grafts.
CONCLUSION
With the AA IA access, we introduced a new technique
and alternative approach after exhaustion of common up-
per extremity access options. This technique might be
particularly suitable for patients with central vein occlusion.
An acceptable perioperative morbidity and an excellent
short-term secondary patency rate could be demonstrated.
Further follow-up is necessary to determine the long-term
complication rate and to allow more reasonable compari-
son with other methods of access.
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